Search clinical trials for: SPP100

Total 131 results

National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Raltitrexed in Treating Children With Refractory Acute Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia

Switzerland
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
Medical University of Graz
Joanneum Research Forschungsgesellschaft mbH

Completed

Bioequivalence of Topical Acyclovir in Healthy Volunteers (FDA_BE1)

Dermatologic Disorders

Austria
Bristol-Myers Squibb

Completed

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Melanoma | Metastases

United States, Canada, Netherlands, United Kingdom, Germany, Chile, Belgium, France, South Africa, Argentina, Brazil, Hungary, Switzerland
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
Princess Maxima Center for Pediatric Oncology
UMC Utrecht; Dutch Cancer Society

Recruiting

Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients. (CATERPILLAR)

Central Line-associated Bloodstream Infection (CLABSI)

Netherlands
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Melanoma

United States
Providence Cancer Center, Earle A. Chiles Research...
National Cancer Institute (NCI)

Completed

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccination During Lymphoid Reconstruction

Intraocular Melanoma | Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Akdeniz University

Recruiting

Evaluation of Neuronal Damage in Patients Undergoing Robot-assisted Laparoscopic Radical Prostatectomy With Biomarkers

Brain Damage | Postoperative | Surgery-Complications

Turkey
University of New Mexico

Withdrawn

Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB) (EIB)

Exercise-induced Bronchospasm

United States
Sunovion

Completed

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Chronic Obstructive Pulmonary Disease

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Actinium Pharmaceuticals

Recruiting

Venetoclax and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Maria Sklodowska-Curie National Research Institute...

Unknown

Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes

Melanoma (Skin)

Poland
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Melanoma | Neoplasm Metastasis

United States
National Cancer Institute (NCI)

Completed

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

Myelodysplastic Syndrome (MDS) | Non-Hodgkin's Lymphoma (NHL) | Leukemia, Acute Myelogenous (AML) | Leukemia, Acute Lymphocytic (ALL) | Leukemia, Chronic Myelogenous (CML)

United States
National Cancer Institute (NCI)

Completed

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Melanoma | Skin Cancer

United States
National Cancer Institute (NCI)

Completed

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Melanoma

United States

Search clinical trials for: SPP100

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations